Geode Capital Management
RANI icon

Geode Capital Management’s Rani Therapeutics RANI Stock Holding History

Geode Capital Management’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$664K Buy
903,298
+42,357
+5% +$54.1K ﹤0.01% 3482
2025
Q4 		$1.16M Buy
860,941
+564,031
+190% +$851K ﹤0.01% 3327
2025
Q3 		$148K Buy
296,910
+106,353
+56% +$55.4K ﹤0.01% 4021
2025
Q2 		$97.9K Sell
190,557
-5,660
-3% -$4.62K ﹤0.01% 4067
2025
Q1 		$247K Buy
196,217
+24,644
+14% +$36.5K ﹤0.01% 3776
2024
Q4 		$235K Sell
171,573
-688
-0.4% -$1.45K ﹤0.01% 3852
2024
Q3 		$372K Buy
172,261
+21,527
+14% +$61.7K ﹤0.01% 3697
2024
Q2 		$573K Buy
150,734
+19,828
+15% +$103K ﹤0.01% 3519
2024
Q1 		$407K Buy
130,906
+17,277
+15% +$59.4K ﹤0.01% 3686
2023
Q4 		$377K Hold
113,629
– – ﹤0.01% 3720
2023
Q3 		$247K Buy
113,629
+16,444
+17% +$62.8K ﹤0.01% 3897
2023
Q2 		$400K Hold
97,185
– – ﹤0.01% 3734
2023
Q1 		$501K Hold
97,185
– – ﹤0.01% 3649
2022
Q4 		$573K Buy
97,185
+2,653
+3% +$19.4K ﹤0.01% 3602
2022
Q3 		$905K Buy
94,532
+21,083
+29% +$223K ﹤0.01% 3438
2022
Q2 		$758K Buy
73,449
+2,183
+3% +$25.1K ﹤0.01% 3541
2022
Q1 		$962K Buy
71,266
+8,049
+13% +$134K ﹤0.01% 3634
2021
Q4 		$1.03M Buy
63,217
+41,578
+192% +$945K ﹤0.01% 3705
2021
Q3 		$385K Buy
+21,639
New +$374K ﹤0.01% 4151

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management's RANI Position: Q1 2026 in Review

Geode Capital Management increased its Rani Therapeutics (RANI) stake by 4.9% in Q1 2026, buying an estimated $54.1K and bringing the position to 903,298 shares worth $664K. The position accounts for ﹤0.01% of the portfolio, ranked #3482.

Geode Capital Management first reported a position in RANI in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.16M in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Geode Capital Management held 903,298 shares of Rani Therapeutics worth $664K as of Q1 2026.
  • Geode Capital Management bought 42,357 Rani Therapeutics shares in Q1 2026, an estimated $54.1K.
  • Rani Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3482 holding.
  • Geode Capital Management first reported a position in Rani Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Geode Capital Management's Rani Therapeutics position peaked at $1.16M in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.